Compare Aspen Aerogels Inc (ASPN) vs Axogen Inc (AXGN) Price & Performance

ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.

Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.

AXGN trades at $40.58, down 6.97% today, with neutral technical signals and mixed earnings performance. The company maintains strong gross margins of 75.01% but reported a net loss of $15.70 million in 2025. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $47.60 consensus price target, representing 17% upside potential from current levels.

While AXGN shows promising revenue growth and institutional support, persistent net losses and recent earnings misses create execution risk. The stock's valuation appears stretched with a P/S ratio of 8.12 despite negative profitability metrics. Positive reimbursement developments and nerve repair market expansion provide growth catalysts if the company can achieve sustained profitability.